#USA #New York #Medtronic #Pulnovo Medical #PADN System

Pulnovo Medical Secures $100 Million Investment from Medtronic

Pulnovo Medical, a leader in groundbreaking treatments for pulmonary hypertension and heart failure, has successfully wrapped up a $100 million oversubscribed financing round. This investment was spearheaded by Medtronic, one of the foremost medical technology firms worldwide. The round saw robust backing not only from Medtronic but also from existing investors such as EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures, with the inclusion of new investors like HSG (formerly Sequoia China).

This substantial funding marks a pivotal milestone for Pulnovo Medical, reinforcing its strategic vision and validating its innovative technology within the health sector. The investment highlights confidence from both strategic and institutional investors in Pulnovo's potential to revolutionize care for patients suffering from cardiopulmonary diseases.

As part of this partnership, Medtronic and Pulnovo have entered a commercial agreement aimed at exploring future collaboration opportunities. This agreement is poised to maximize commercial synergy, leveraging Medtronic's extensive global reach and distribution capabilities, which could streamline the introduction of Pulnovo's novel therapies into various markets.

Pulnovo’s proprietary Pulmonary Artery Denervation (PADN) System stands at the forefront of its innovative technologies. This first-in-class, minimally invasive procedure targets a significant underlying cause of cardiopulmonary diseases by modulating the overactive sympathetic nerve activity that contributes to pulmonary vascular remodeling. Early clinical results have shown promising benefits, including improved patient outcomes and better functional capacity.

As evidence of its credibility, Pulnovo Medical has conducted around 1,500 PADN procedures globally and has attained regulatory approvals in seven countries, with aspirations for further-reaching commercialization efforts across the European Union, Middle East, and China. In the United States, the FDA has awarded the PADN System Breakthrough Device Designation, and two Investigational Device Exemption (IDE) clinical trials have been launched under the leadership of Dr. Gregg Stone from Mount Sinai.

Cynthia Chen, Chairlady and President of Pulnovo Medical, expressed, "Through the integration of industry expertise and long-term capital, Pulnovo is building a scalable growth model anchored in proprietary innovation, global clinical development, and strategic ecosystem partnerships." She emphasized that the recent financing signifies a transformation from being product-driven to establishing a fully integrated global platform. This reorientation maintains a steadfast commitment to innovation aimed at enhancing patient care on a global scale.

With the infusion of capital, Pulnovo is set to accelerate its clinical development efforts, navigate global regulatory challenges, and ramp up commercial operations. Further, to strengthen its market presence, Andre Xiao has joined the company as Chief Strategy Officer, focusing on global financing and strategy. His extensive background in healthcare investment, particularly in MedTech, will prove invaluable as Pulnovo aspires to establish deeper connections with investors and partners worldwide.

Advances in Pulmonary Artery Denervation

Pulnovo's PADN System has been recognized as a promising therapy option in diverse international clinical guidelines, including those issued by the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) regarding pulmonary hypertension management.

Ongoing clinical studies, including trials in Europe and Asia, are nearing completion and are expected to enhance the understanding of PADN's efficacy. The PULSE-LHD IDE trial, recently initiated in the United States, will further substantiate the clinical profile of the PADN procedure, addressing the urgent unmet needs in heart failure and associated cardiopulmonary conditions.

Anticipating a brighter future, Pulnovo Medical’s commitment lies in its pursuit of innovative solutions designed to transform the treatment landscape for patients with heart conditions globally. Their dedication to advancing interventional therapies reflects an unwavering mission to improve patient outcomes through their innovative technologies and partnerships.

In conclusion, the strategic backing from Medtronic signifies a robust collaborative framework that will likely amplify Pulnovo’s reach and impact in the field of cardiology, contributing positively to managing some of the most challenging heart diseases of our time.